HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neutrogena skin care

This article was originally published in The Rose Sheet

Executive Summary

ProCyte licenses copper peptide patents to Neutrogena for development of "skin health" products, ProCyte announces. The copper peptide technology has been shown to have a "very positive effect" on fine lines/wrinkles, and aids in collagen and elastin formation, the supplier claims. Neutrogena reviewed two ProCyte complexes for hair and skin care, but decided not to pursue the hair care technology. ProCyte is in similar licensing agreement with Osmotics for the prestige market

You may also be interested in...



Neutrogena Visibly Firm Takes Elemental Approach With Active Copper

Neutrogena Visibly Firm Night and Eye creams employ the nutrient copper to restore skin firmness and regain measurably smooth, buoyant skin, the Johnson & Johnson division said at a press event in New York City Feb. 20.

Neutrogena Visibly Firm Takes Elemental Approach With Active Copper

Neutrogena Visibly Firm Night and Eye creams employ the nutrient copper to restore skin firmness and regain measurably smooth, buoyant skin, the Johnson & Johnson division said at a press event in New York City Feb. 20.

Neutrogena Growth Rests In Existing Categories - CEO McNamara

Neutrogena's double-digit growth strategy calls for product expansion in existing categories, with new introductions that extend the company's foundation of products "grounded in real results for both the health and beauty of skin and hair," CEO Michael McNamara said.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel